The Formulation of Recombinant Collagen Materials as Coatings in Medical Devices
Lead Research Organisation:
Swansea University
Department Name: College of Engineering
Abstract
Background:
ProColl is a supplier of bovine and recombinant collagen for application within medical devices, cell culture, tissue engineering, pharmaceuticals, and cosmetics. The company was founded as a spin out from Swansea University in 2018 to bring to market the improved scale production of collagen with exceptional quality and purity. The company then developed techniques to produce recombinant collagen to answer the market need for animal free collagen that is more biocompatible, ethically robust and removes the risk of interspecies transfer of disease.
Collagen is the most abundant protein within the human body and plays a central role in the maintenance and repair of all organs and tissues. Collagen has a structural role as the glue that anchors and houses cells within the extracellular matrix of tissues. Thus, it is one of the most industrially important proteins with applications as a functional, structural material in medicine, cosmetics, and food. Within medicine and cell research collagen is predominantly used as a gel or a coating; the collagen is used to coat cell culture materials to allow adhesion and subsequent development of the cells. Through collaboration with Swansea University, ProColl currently produce recombinant human Type I collagen molecules with the view to expand this to other collagen types.
The research of the project will develop advanced materials in the form of new recombinant collagen materials and novel collagen formulations that are optimised for the coating of surfaces and application within cell culture, tissue engineering and wound healing. The recombinant collagen will be produced through fermentation in a sustainable process that removes the need for bovine sources and their accompanying impact on the environment. In addition, alternative raw materials for the fermentation will be investigated to further improve sustainability. The collagen surfaces will be characterised in terms of coating film morphology, biocompatibility and mechanical resilience using advanced techniques including atomic force microscopy, scanning electron microscopy, dynamic and fatigue testing systems, and cell culture. The project will examine different coating methods such as layer by layer, lyophilisation, spray coating, casting and electrospinning to control the morphology and functionality of the collagen coatings.
Project Aims:
The outcomes of the project will be the creation of new and improved processes for the manufacture of recombinant collagen. A range of novel surface coatings will be developed that are optimised for application within research and medicine. The research needed to achieve these outcomes will provide comprehensive and novel insights into collagen materials which is of interest to the academic community and will be published. The research will also be disseminated at key international conferences. ProColl will commercialise the new processes and products creating industrial impact and benefit to Welsh and UK economies.
ProColl is a supplier of bovine and recombinant collagen for application within medical devices, cell culture, tissue engineering, pharmaceuticals, and cosmetics. The company was founded as a spin out from Swansea University in 2018 to bring to market the improved scale production of collagen with exceptional quality and purity. The company then developed techniques to produce recombinant collagen to answer the market need for animal free collagen that is more biocompatible, ethically robust and removes the risk of interspecies transfer of disease.
Collagen is the most abundant protein within the human body and plays a central role in the maintenance and repair of all organs and tissues. Collagen has a structural role as the glue that anchors and houses cells within the extracellular matrix of tissues. Thus, it is one of the most industrially important proteins with applications as a functional, structural material in medicine, cosmetics, and food. Within medicine and cell research collagen is predominantly used as a gel or a coating; the collagen is used to coat cell culture materials to allow adhesion and subsequent development of the cells. Through collaboration with Swansea University, ProColl currently produce recombinant human Type I collagen molecules with the view to expand this to other collagen types.
The research of the project will develop advanced materials in the form of new recombinant collagen materials and novel collagen formulations that are optimised for the coating of surfaces and application within cell culture, tissue engineering and wound healing. The recombinant collagen will be produced through fermentation in a sustainable process that removes the need for bovine sources and their accompanying impact on the environment. In addition, alternative raw materials for the fermentation will be investigated to further improve sustainability. The collagen surfaces will be characterised in terms of coating film morphology, biocompatibility and mechanical resilience using advanced techniques including atomic force microscopy, scanning electron microscopy, dynamic and fatigue testing systems, and cell culture. The project will examine different coating methods such as layer by layer, lyophilisation, spray coating, casting and electrospinning to control the morphology and functionality of the collagen coatings.
Project Aims:
The outcomes of the project will be the creation of new and improved processes for the manufacture of recombinant collagen. A range of novel surface coatings will be developed that are optimised for application within research and medicine. The research needed to achieve these outcomes will provide comprehensive and novel insights into collagen materials which is of interest to the academic community and will be published. The research will also be disseminated at key international conferences. ProColl will commercialise the new processes and products creating industrial impact and benefit to Welsh and UK economies.
People |
ORCID iD |
| Hari Arora (Primary Supervisor) | |
| Charlotte Fricker (Student) |
Studentship Projects
| Project Reference | Relationship | Related To | Start | End | Student Name |
|---|---|---|---|---|---|
| EP/S02252X/1 | 01/10/2019 | 31/03/2028 | |||
| 2886087 | Studentship | EP/S02252X/1 | 01/10/2023 | 30/09/2027 | Charlotte Fricker |